• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中的肠道微生物群与铁死亡

The Gut Microbiome and Ferroptosis in MAFLD.

作者信息

Ji Jie, Wu Liwei, Wei Jue, Wu Jianye, Guo Chuanyong

机构信息

Department of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, China.

Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.

出版信息

J Clin Transl Hepatol. 2023 Feb 28;11(1):174-187. doi: 10.14218/JCTH.2022.00136. Epub 2022 Jul 14.

DOI:10.14218/JCTH.2022.00136
PMID:36406312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9647110/
Abstract

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and is proposed to replace the previous name, nonalcoholic fatty liver disease (NAFLD). Globally, MAFLD/NAFLD is the most common liver disease, with an incidence rate ranging from 6% to 35% in adult populations. The pathogenesis of MAFLD/NAFLD is closely related to insulin resistance (IR), and the genetic susceptibility to acquired metabolic stress-associated liver injury. Similarly, the gut microbiota in MAFLD/NAFLD is being revaluated by scientists, as the gut and liver influence each other via the gut-liver axis. Ferroptosis is a novel form of programmed cell death caused by iron-dependent lipid peroxidation. Emerging evidence suggests that ferroptosis has a key role in the pathological progression of MAFLD/NAFLD, and inhibition of ferroptosis may become a novel therapeutic strategy for the treatment of NAFLD. This review focuses on the main mechanisms behind the promotion of MAFLD/NAFLD occurrence and development by the intestinal microbiota and ferroptosis. It outlines new strategies to target the intestinal microbiota and ferroptosis to facilitate future MAFLD/NAFLD therapies.

摘要

代谢相关脂肪性肝病(MAFLD)是一种新的疾病定义,旨在取代先前的名称——非酒精性脂肪性肝病(NAFLD)。在全球范围内,MAFLD/NAFLD是最常见的肝脏疾病,在成年人群中的发病率为6%至35%。MAFLD/NAFLD的发病机制与胰岛素抵抗(IR)以及对获得性代谢应激相关肝损伤的遗传易感性密切相关。同样,MAFLD/NAFLD中的肠道微生物群正受到科学家们的重新评估,因为肠道和肝脏通过肠-肝轴相互影响。铁死亡是一种由铁依赖性脂质过氧化引起的新型程序性细胞死亡形式。新出现的证据表明,铁死亡在MAFLD/NAFLD的病理进展中起关键作用,抑制铁死亡可能成为治疗NAFLD的一种新的治疗策略。这篇综述重点关注肠道微生物群和铁死亡促进MAFLD/NAFLD发生发展的主要机制。它概述了针对肠道微生物群和铁死亡的新策略,以促进未来MAFLD/NAFLD的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e51b/9647110/83ca36d7f0a5/JCTH-11-174-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e51b/9647110/4b149133a116/JCTH-11-174-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e51b/9647110/83ca36d7f0a5/JCTH-11-174-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e51b/9647110/4b149133a116/JCTH-11-174-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e51b/9647110/83ca36d7f0a5/JCTH-11-174-g002.jpg

相似文献

1
The Gut Microbiome and Ferroptosis in MAFLD.非酒精性脂肪性肝病中的肠道微生物群与铁死亡
J Clin Transl Hepatol. 2023 Feb 28;11(1):174-187. doi: 10.14218/JCTH.2022.00136. Epub 2022 Jul 14.
2
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.肠-肝轴:非酒精性脂肪性肝病和 2 型糖尿病的新机制和治疗方法。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8421-8443. doi: 10.1007/s00210-024-03204-6. Epub 2024 Jun 11.
3
Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?铁死亡与代谢相关脂肪性肝病:有关联吗?
Liver Int. 2022 Jul;42(7):1496-1502. doi: 10.1111/liv.15163. Epub 2022 Jan 23.
4
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.肠道微生物群和免疫细胞在代谢相关脂肪性肝病中的作用:临床影响。
Hepatol Int. 2024 Oct;18(Suppl 2):861-872. doi: 10.1007/s12072-024-10674-6. Epub 2024 Jul 12.
5
The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin-linked MAFLD.肠道微生物群代谢产物甘氨胆酸激活 TFR-ACSL4 介导的铁死亡,促进环境毒素相关 MAFLD 的发生发展。
Free Radic Biol Med. 2022 Nov 20;193(Pt 1):213-226. doi: 10.1016/j.freeradbiomed.2022.10.270. Epub 2022 Oct 17.
6
Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies.铁死亡在非酒精性脂肪性肝病中的作用及其对治疗策略的启示
Biomedicines. 2021 Nov 10;9(11):1660. doi: 10.3390/biomedicines9111660.
7
Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.膳食营养素对与代谢功能障碍相关的脂肪性肝病(MAFLD)的影响:基于肠-肝轴
Front Nutr. 2022 Jun 17;9:906511. doi: 10.3389/fnut.2022.906511. eCollection 2022.
8
Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.非酒精性脂肪性肝病进展中的肠-肝轴:以微生物衍生物为中心的视角
Life Sci. 2023 May 15;321:121614. doi: 10.1016/j.lfs.2023.121614. Epub 2023 Mar 24.
9
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.代谢相关脂肪性肝病(MAFLD)发病机制的新见解:肠-肝-心轴的相互作用
Nutrients. 2023 Sep 14;15(18):3970. doi: 10.3390/nu15183970.
10
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).代谢相关脂肪性肝病(MAFLD)中的线粒体功能障碍。
Int J Mol Sci. 2023 Dec 15;24(24):17514. doi: 10.3390/ijms242417514.

引用本文的文献

1
Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights.代谢相关脂肪性肝病时代的酒精消费与肝脏代谢:整合营养与病理生理学见解
Nutrients. 2025 Jul 5;17(13):2229. doi: 10.3390/nu17132229.
2
Ferroptosis in Gastrointestinal Diseases: A New Frontier in Pathogenesis and Therapy.胃肠道疾病中的铁死亡:发病机制与治疗的新前沿
J Clin Med. 2025 Jun 7;14(12):4035. doi: 10.3390/jcm14124035.
3
Diagnosis of Cholangiocarcinoma: The New Biological and Technological Horizons.胆管癌的诊断:新的生物学与技术前沿

本文引用的文献

1
Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies.铁死亡在非酒精性脂肪性肝病中的作用及其对治疗策略的启示
Biomedicines. 2021 Nov 10;9(11):1660. doi: 10.3390/biomedicines9111660.
2
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).2 型糖尿病伴非酒精性脂肪性肝病的胰高血糖素样肽 1 受体激动剂(GLP1-RA)作用的荟萃分析。
Sci Rep. 2021 Nov 11;11(1):22063. doi: 10.1038/s41598-021-01663-y.
3
Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells.
Diagnostics (Basel). 2025 Apr 16;15(8):1011. doi: 10.3390/diagnostics15081011.
4
HIIT versus MICT in MASLD: mechanisms mediated by gut-liver axis crosstalk, mitochondrial dynamics remodeling, and adipokine signaling attenuation.高强度间歇训练与中等强度持续训练治疗非酒精性脂肪性肝病合并代谢综合征:由肠-肝轴串扰、线粒体动力学重塑和脂肪因子信号衰减介导的机制
Lipids Health Dis. 2025 Apr 16;24(1):144. doi: 10.1186/s12944-025-02565-y.
5
N6-Methyladenosine Modification in the Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病中的N6-甲基腺苷修饰
Nutrients. 2025 Mar 27;17(7):1158. doi: 10.3390/nu17071158.
6
A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies.代谢功能障碍相关脂肪性肝病综合评述:聚焦甲基乙二醛的发病机制及平衡治疗策略
Int J Mol Sci. 2025 Mar 7;26(6):2394. doi: 10.3390/ijms26062394.
7
Cutting edge: ferroptosis in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis and therapy.前沿:铁死亡在代谢功能障碍相关脂肪性肝病(MASLD)发病机制及治疗中的作用
Funct Integr Genomics. 2025 Mar 25;25(1):71. doi: 10.1007/s10142-025-01579-0.
8
From mechanisms to medicine: Ferroptosis as a Therapeutic target in liver disorders.从机制到医学:铁死亡作为肝脏疾病的治疗靶点
Cell Commun Signal. 2025 Mar 7;23(1):125. doi: 10.1186/s12964-025-02121-2.
9
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.肠道微生物群处于肝脏氧化应激与代谢相关脂肪性肝病的交叉点
Antioxidants (Basel). 2025 Jan 6;14(1):56. doi: 10.3390/antiox14010056.
10
ABL1‒YAP1 axis in intestinal stem cell activated by deoxycholic acid contributes to hepatic steatosis.脱氧胆酸激活的肠道干细胞中的ABL1-YAP1轴导致肝脂肪变性。
J Transl Med. 2024 Dec 20;22(1):1119. doi: 10.1186/s12967-024-05865-6.
Fin56 诱导的铁死亡受到自噬介导的 GPX4 降解的支持,并与 mTOR 抑制协同作用,杀死膀胱癌细胞。
Cell Death Dis. 2021 Oct 29;12(11):1028. doi: 10.1038/s41419-021-04306-2.
4
Ferroptosis in liver disease: new insights into disease mechanisms.肝病中的铁死亡:对疾病机制的新见解
Cell Death Discov. 2021 Oct 5;7(1):276. doi: 10.1038/s41420-021-00660-4.
5
GPX4 and vitamin E cooperatively protect hematopoietic stem and progenitor cells from lipid peroxidation and ferroptosis.GPX4 和维生素 E 协同保护造血干/祖细胞免受脂质过氧化和铁死亡。
Cell Death Dis. 2021 Jul 15;12(7):706. doi: 10.1038/s41419-021-04008-9.
6
Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.胰高血糖素样肽-1受体激动剂在非酒精性脂肪性肝炎管理中的作用:一篇临床综述文章。
Cureus. 2021 May 20;13(5):e15141. doi: 10.7759/cureus.15141.
7
Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome.铁状态通过肠道微生物群影响肥胖的非酒精性脂肪肝疾病。
Microbiome. 2021 May 7;9(1):104. doi: 10.1186/s40168-021-01052-7.
8
Short-chain free-fatty acid G protein-coupled receptors in colon cancer.结直肠癌中的短链游离脂肪酸 G 蛋白偶联受体。
Biochem Pharmacol. 2021 Apr;186:114483. doi: 10.1016/j.bcp.2021.114483. Epub 2021 Feb 23.
9
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.恩格列净通过激活自噬和减少内质网应激和细胞凋亡减轻高脂饮食喂养的载脂蛋白 E 小鼠的非酒精性脂肪性肝病 (NAFLD)。
Int J Mol Sci. 2021 Jan 15;22(2):818. doi: 10.3390/ijms22020818.
10
The role of the gut microbiome and its metabolites in metabolic diseases.肠道微生物组及其代谢产物在代谢性疾病中的作用。
Protein Cell. 2021 May;12(5):360-373. doi: 10.1007/s13238-020-00814-7. Epub 2020 Dec 21.